Wednesday, December 9, 2015

Treatment for MS does well in phase 3 trials

(since this is one of the misdiagnoses of Lyme, maybe it will interest some)

Anti-CD20 antibody wows in multiple sclerosis

Nature Biotechnology
Published online
09 December 2015
Jessica Wilson / Science Source
MRI of normal brain (left) and one with multiple sclerosis (right).
Roche plans to seek approval early in the new year for its anti-CD20 antibody ocrelizumab as therapy in both forms of multiple sclerosis (MS)—primary progressive and relapsing remitting—following positive outcomes from recent phase 3 trials.

No comments:

Post a Comment

Please be constructive in your comments.